Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
0.913 USD | +2.90% | +6.41% | +11.67% |
Apr. 25 | Transcript : HOOKIPA Pharma Inc. - Special Call | |
Apr. 25 | HOOKIPA Pharma Inc. Announces Pivotal Phase 2/3 Trial Design for HB-200 in Combination with Pembrolizumab | CI |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+11.67% | 87.8M | |
+33.67% | 704B | |
+28.38% | 577B | |
-4.90% | 348B | |
+17.44% | 327B | |
+4.48% | 288B | |
+14.94% | 234B | |
+4.93% | 198B | |
-9.78% | 194B | |
-4.97% | 147B |
- Stock Market
- Equities
- HOOK Stock
- News HOOKIPA Pharma Inc.
- Morgan Stanley Downgrades HOOKIPA Pharma to Equal-Weight From Overweight; Price Target is $6